GlassScriptPhysician profile
Jamie Lynn Tracy
NPI 1699429571
$1,671.09
in general payments reported to CMS, 2019-2025
24 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $359 · 2023: $313 · 2024: $598 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $231.57 | 2022-2025 | Evenity, Prolia |
| Abbvie INC. | $224.29 | 2023-2025 | |
| Lilly USA, LLC | $209.85 | 2022-2025 | Mounjaro, Zepbound |
| Grifols USA, LLC | $172.01 | 2022-2024 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $132.64 | 2024 | Breztri, Farxiga, Airsupra |
| Daiichi Sankyo INC. | $91.12 | 2022-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $76.53 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.49 | 2022-2024 | Ofev, Jardiance |
| Pfizer INC. | $64.68 | 2023-2025 | |
| Novo Nordisk INC | $50.85 | 2022-2024 | |
| Exact Sciences Corporation | $46.37 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $41.03 | 2022-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $37.03 | 2022 | |
| Astellas Pharma US INC | $31.52 | 2024 | Veozah |
| Collegium Pharmaceutical, INC. | $31.21 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $28.00 | 2023-2025 | Nexplanon |
| Abiomed | $25.68 | 2024 | Impella |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.99 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $17.89 | 2024 | |
| Abbott Laboratories | $15.16 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $14.86 | 2024 | Rexulti |
| Ucb, INC. | $14.08 | 2023 | Cimzia |
| Actelion Pharmaceuticals US, INC. | $13.25 | 2024 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Tracy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.